Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Multiple Myeloma 2Neuroblastoma 1Ganglioneuroblastoma 1

Interventions

dinutuximab 4sargramostim 3Topotecan 3Cyclophosphamide 3Colony-Stimulating Factors 3Vincristine 2Thiotepa 2Temozolomide 2Stem Cell Transplantation 2Radiation 2Platinum 2Melphalan 2Magnetic Resonance Spectroscopy 2Isotretinoin 2Irinotecan 2Etoposide 2Doxorubicin 2Cisplatin 2Carboplatin 2Biopsy 21,2-diaminocyclohexaneplatinum II citrate 2temsirolimus 1iberdomide 1Transurethral Resection of Bladder 1Specimen Handling 1Sirolimus 1Razoxane 1Radiotherapy 1Nuclear Medicine Department, Hospital 1Leukapheresis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Ganglioneuroblastoma × iberdomide × Clear all
NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
76 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡